Regeneron Pharmaceuticals, Inc. REGN
Set alert
At close · Oct 30
After hours · Oct 30, 4:44 PM ET
- YTD
- +20.21%
- 1 year
- +41.87%
- Open
- 869.43
- Prev close
- 818.77
- Mkt cap
- 95.53B
- Vol
- 2.85M
- Avg vol
- 707.20K
- EPS
- 40.44
- P/E
- 22.94
- Div yield
- 0.46%
More statistics
- Low
- 839.08
- High
- 935.34
- Forward P/E
- 14.74
- Beta
- 0.15
- Short ratio
- 2.78
- Inst. own
- 93.18%
- Dividend
- 3.76
- Ex-div date
- Aug 17, 2026
- Earnings
- Jan 29, 2027
- 50-d avg
- 791.28
- 200-d avg
- 736.67
- 1y target
- 869.07
5D chart
Events in this range
- Oct 28, 2026Rating: Canaccord Genuity · Buy → Buy
- Oct 30, 2026Earnings: 20.07; estimate 16.51; surprise 21.56%
Signals (128)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 2:55 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:50 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:50 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 2:45 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:40 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:35 PM | 1 day ago |
| RSI: Overbought | Oct 30, 2:25 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:20 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 2:20 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:15 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:05 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:05 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:55 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:50 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:40 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:15 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:40 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:35 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:30 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:20 PM | 1 day ago |
| SMA: Bearish | Oct 30, 11:55 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:30 AM | 1 day ago |
| SMA: Bullish | Oct 30, 11:25 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:05 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:40 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 10:30 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:15 AM | 1 day ago |
| RSI: Overbought | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bullish | Oct 29, 3:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:55 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 11:50 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 11:25 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:25 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| RSI: Oversold | Oct 28, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 3 days ago |
| SMA: Bearish | Oct 28, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:00 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:35 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 9:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 27, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:10 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:15 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 10:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 4 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 4 days ago |
| RSI: Overbought | Oct 26, 3:50 PM | 5 days ago |
| RSI: Overbought | Oct 26, 3:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:45 PM | 5 days ago |
| RSI: Oversold | Oct 26, 12:20 PM | 5 days ago |
| RSI: Oversold | Oct 26, 11:35 AM | 5 days ago |
| RSI: Oversold | Oct 26, 11:05 AM | 5 days ago |
| RSI: Oversold | Oct 26, 10:55 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:25 AM | 5 days ago |
News
19 hours ago fool.com
Regeneron: 3 Key Takeaways for Long-Term Investors
Dupixent global quarterly net sales grew 35% year over year to $6.5 billion. Total revenue increased 36% year over year to $5.1 billion.
1 day ago benzinga.com
Alphabet Posts Worst Week Since 2011, Intel Suffers Record Crash as Warsh Sees 'Cracks': This Week on Wall Street
Alphabet logs its worst week since 2011 and Intel its worst day ever as the AI trade cracks, while health care posts a record month against the market.
1 day ago zacks.com
REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
Regeneron's Q3 earnings and revenues beat estimates, fueled by strong Dupixent profits, Eylea HD growth and robust Libtayo demand. Stock up.
1 day ago seekingalpha.com
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript
1 day ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday.…
1 day ago benzinga.com
Nasdaq Tumbles Over 3%, Chip Stocks Sink: Stock Market Today
Intel nears its worst day on record after weak guidance, sinking chip stocks as SMH falls 7.0% and the Nasdaq 100 drops 3.2%.
1 day ago benzinga.com
Regeneron Eyes One of Its Strongest Years Ever, Stock Jumps
Regeneron stock hits a 52-week high as earnings surge 70%, revenue jumps 36% and key drugs deliver record sales.
1 day ago seekingalpha.com
Regeneron Is Just Getting Started
Regeneron delivered a standout Q3, with net sales up 36% year-over-year to $5.1 billion, driven mainly by Dupixent's outperformance. Eylea HD and Libtayo posted strong growth, while Eylea 2 mg showed…
1 day ago marketbeat.com
What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call
Regeneron Pharmaceuticals NASDAQ: REGN reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company…
1 day ago 247wallst.com
Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs
Regeneron (NASDAQ:REGN | REGN Price Prediction) shares rose 13.55% in Friday's session, trading at $929.69 as of 9:45 AM ET on Oct 30, 2026. For a biotech worth roughly $94.
1 day ago 247wallst.com
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron…
1 day ago zacks.com
Regeneron (REGN) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
1 day ago benzinga.com
AutoNation, Regeneron Pharmaceuticals, AstraZeneca And Other Big Stocks Moving Higher On Friday
U.S. stocks fell Friday, but AutoNation jumped 8% after beating Q3 estimates; OneSpan, Grid Dynamics and others posted double-digit gains.
1 day ago benzinga.com
Regeneron Pharmaceuticals Q3 2026 Earnings Call Transcript
Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
1 day ago zacks.com
Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates
Regeneron (REGN) came out with quarterly earnings of $20.07 per share, beating the Zacks Consensus Estimate of $16.08 per share. This compares to earnings of $11.83 per share a year ago.
-
2 days ago benzinga.com
Regeneron Pharmaceuticals Q3 Adj. EPS $20.07 Beats $16.19 Estimate, Sales $5.116B Beat $4.542B Estimate
Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $20.07 per share which beat the analyst consensus estimate of $16.19 by 23.97 percent. This is a 69.65 percent increase over…
2 days ago globenewswire.com
Regeneron Reports Third Quarter 2026 Financial and Operating Results
TARRYTOWN, N.Y., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the third quarter of 2026 and provided a business update.
2 days ago benzinga.com
Top Wall Street Forecasters Revamp Regeneron Pharmaceuticals Expectations Ahead Of Q3 Earnings
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will release its third quarter earnings report before the opening bell on Friday, Oct. 30.
2 days ago benzinga.com
Top Wall Street Forecasters Revamp Regeneron Pharmaceuticals Expectations Ahead Of Q3 Earnings
Regeneron expects Q3 EPS of $16.19 and revenue of $4.56B; extended BARDA’s Inmazeb supply deal as analysts raise price targets.
2 days ago benzinga.com
ExxonMobil, AbbVie On Deck Friday As Energy, Drug Growth Face Test
ExxonMobil headlines Friday’s reports, with investors watching whether strong energy production can sustain a sharp earnings recovery. AbbVie, Chevron, AstraZeneca, BP, Sanofi, General Dynamics,…
-
3 days ago benzinga.com
Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $922
Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $875 to $922.
3 days ago seekingalpha.com
Regeneron Earnings Preview: Dupixent Is Booming, But It's Still Overvalued
Regeneron Pharmaceuticals is rated Sell at $808, with a fair value of ~$675, implying a 16.4% downside risk. Dupixent's growth is strong, but patent expiration in 2031 and biosimilar risks cap…
4 days ago benzinga.com
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 6.58% on an annualized basis producing an average annual return of 19.53%. Currently, Regeneron…
5 days ago zacks.com
Here's Why Regeneron (REGN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 days ago 247wallst.com
Regeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 Earnings
Regeneron (NASDAQ:REGN | REGN Price Prediction) reports third-quarter results on Oct. 30. Regeneron books its full share of Dupixent profits from Sanofi (NASDAQ:SNY) for the first time this quarter.
-
5 days ago benzinga.com
Regeneron Pharma Extends Agreement With BARDA, Part Of ASPR Within US Department Of HHS, To Provide Additional Supply Of Inmazeb For US Preparedness Against Ebola Disease
Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 millionTARRYTOWN,…
5 days ago globenewswire.com
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense , adding value of approximately $270 million
1 week ago globenewswire.com
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the…
1 week ago defenseworld.net
Evergreen Capital Management LLC Sells 3,547 Shares of Regeneron Pharmaceuticals, Inc. $REGN
Evergreen Capital Management LLC lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 20.0% during the third quarter, according to its most recent Form 13F filing with the…
-
1 week ago benzinga.com
TD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $980
TD Cowen analyst Tyler Van Buren maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $960 to $980.
-
1 week ago benzinga.com
Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865
Piper Sandler analyst Biren Amin maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $854 to $865.
-
2 weeks ago benzinga.com
Regeneron Pharma Says EMA’s CHMP Adopts Positive Opinion Recommending Approval Of Alternative Dosing Schedule For Libtayo Across All Approved Indications
Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatmentOptional reduction of infusion time for 350 mg dose to 15 to 30…
-
2 weeks ago benzinga.com
UBS Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $978
UBS analyst Trung Huynh upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Neutral to Buy and raises the price target from $660 to $978.
2 weeks ago benzinga.com
Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth
Regeneron's Pasatru shows sustained efficacy in halting new bone growth and reducing flare-ups in adults with FOP in an 84-week trial.
-
2 weeks ago benzinga.com
Regeneron Pharmaceuticals Announces Data From Its Phase 3 OPTIMA Study Of Pasatru To Treat Fibrodysplasia Ossificans Progressiva Shows Efficacy In Stopping New Bone Growth; Trial Meets Primary Endpoint By Reducing 90% New Heterotopic Ossification Lesions
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive 84-week results from the Phase 3 OPTIMA trial evaluating Pasatru™ (garetosmab-grts) in adults with fibrodysplasia ossificans…
-
3 weeks ago benzinga.com
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810
RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $737 to $810.
-
3 weeks ago benzinga.com
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780
Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $772 to $780.
-
3 weeks ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779
Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $758 to $779.
-
3 weeks ago benzinga.com
JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950
JP Morgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $900 to $950.
3 weeks ago benzinga.com
Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average
The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQQ has beaten equal-weight QQQE by 8% since late July.
4 weeks ago benzinga.com
Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data
Regeneron reports positive trial data for ubamatamab in ovarian cancer and trevogrumab for muscle preservation during weight loss.
-
1 month ago benzinga.com
Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930
Jefferies analyst Akash Tewari maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $870 to $930.
1 month ago benzinga.com
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Analysts upgraded BJRI, UTHR, OXY, BP and REGN, raising ratings and/or price targets.
-
1 month ago benzinga.com
Regeneron Pharmaceuticals Announces Its Results From Phase 2 COURAGE Study Of Trevogrumab Shows 70% Prevention Of Muscle Loss Associated With Semaglutide Treatment; Lower Dose Of Trevogrumab Did Not Enhance Weight Loss Achieved With Semaglutide Alone
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new results from the Phase 2 COURAGE trial evaluating trevogrumab (anti-GDF8/anti-myostatin) for its potential to prevent lean mass and…
1 month ago benzinga.com
Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion
Regeneron and Sanofi expand their 20-year antibody collaboration with a $1 billion upfront payment and new clinical trials.
-
1 month ago benzinga.com
Argus Research Upgrades Regeneron Pharmaceuticals to Buy, Announces $850 Price Target
Argus Research analyst Jasper Hellweg upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Hold to Buy and announces $850 price target.
note.com
[US Stocks Weekend Report] A week where semiconductors collapsed. Biotech and defensive sectors were strong (10/26–10/30)
Although it rose for three consecutive days from Monday to Wednesday, it collapsed on Thursday with a 1.42% drop and on ...
-
note.com
Overview of Yesterday's NY Stock Market (October 29, 2026) - Economy
Nasdaq: 26,184.73 (-1.38%) Although revenue for the July-September quarter exceeded expectations, the outlook for the October-December quarter fell significantly short of forecasts, and Intel (INTC)…
stockstotrade.com
Inovio Pharmaceuticals Surges After VOCERYQ Wins FDA Approval
Inovio Pharmaceuticals Inc. stocks have been trading up by 166.91 percent following highly positive drug pipeline advancement ...
ainvest.com
Two Suspected Ebola Cases Reported in Nigeria’s North-East
Nigeria reports two suspected Ebola cases in northeast, but outbreak-linked companies earn revenue from pre-signed government ...